Dnia Wed, 30 Jun 2021 10:14:07 +0200, J.F napisał(a):

>> A tu masz wzmiankowany artykuł:
>> https://www.nejm.org/doi/full/10.1056/nejmoa2034577
>
> Nie trzeba :-)
> W jakim kraju testowali ... nie napisali.

Rutynowo nawet nie kliknąłeś albo przeczytałeś nagłówek i dalej jedziesz po
swojemu:

"Between July 27, 2020, and November 14, 2020, a total of 44,820 persons
were screened, and 43,548 persons 16 years of age or older underwent
randomization at 152 sites worldwide (United States, 130 sites; Argentina,
1; Brazil, 2; South Africa, 4; Germany, 6; and Turkey, 9) in the phase 2/3
portion of the trial. A total of 43,448 participants received injections:
21,720 received BNT162b2 and 21,728 received placebo (Figure 1). At the
data cut-off date of October 9, a total of 37,706 participants had a median
of at least 2 months of safety data available after the second dose and
contributed to the main safety data set. Among these 37,706 participants,
49% were female, 83% were White, 9% were Black or African American, 28%
were Hispanic or Latinx, 35% were obese (body mass index [the weight in
kilograms divided by the square of the height in meters] of at least 30.0),
and 21% had at least one coexisting condition. The median age was 52 years,
and 42% of participants were older than 55 years of age "


--
uzdrawiam
Grzesiek

adres: grzegorz.tracz[NA]ifj.edu.pl

"Bóg stworzył człowieka, ponieważ rozczarował się małpą.
Z dalszych eksperymentów zrezygnował."
Mark Twain

http://grzegorz-tracz.ucoz.pl/